Loading...
01/11 03:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects a challenging financial situation with declining organic sales, adjusted gross margin, and operating margin. The absence of a share buyback or dividend program further dampens investor sentiment. While management expressed optimism about innovation and growth in the latter half of the year, the lack of specific guidance and clarity in responses, particularly concerning tariff impacts and innovation success tracking, adds uncertainty. The overall sentiment is negative due to these factors, despite some positive consumer response and planned strategic investments.
Organic Sales $2.5 billion, down 1.2% year-over-year due to a 3% to 4% headwind from destocking in China and strategic investments in price and trade spend in the U.S.
Adjusted Gross Margin 60%, down 20 basis points year-over-year due to volume deleverage, unfavorable currency, inflationary headwinds, and price investments.
Adjusted Operating Margin 19.8%, down 220 basis points year-over-year, driven by increased brand support investments initiated last year.
Adjusted Net Income $465 million, down slightly year-over-year, with a $0.02 headwind from currency.
Adjusted Diluted EPS $0.24, flat year-over-year, with low-single-digit headwind from currency.
Net Interest Expense $94 million, down slightly year-over-year.
Adjusted Effective Tax Rate 27.5%, down slightly year-over-year.
New Product Launches: Launched new Beauty to a Science brand positioning for Neutrogena, supported by a 360-degree media campaign featuring Gen Z influencers.
Innovation in Skin Health: Activated strong innovation slate for Neutrogena and Aveeno, leading to double-digit volume growth in key offerings.
Expansion of Product Lines: Expanding Band-Aid brand and Aveeno Kids ranges with new product variants.
Market Share Growth: Tylenol gained share for the eleventh straight quarter, maintaining its number one position in the US.
Category Leadership: Zyrtec grew both value and volume share, strengthening Kenvue's leadership in the allergy category.
Geographic Expansion: Aveeno brand saw double-digit growth in EMEA, with successful rollout across new doors in Central Europe.
Operational Efficiency: Completed Transition Services Agreement program, finalizing exit of over 2,300 TSAs without disruption.
Cost Structure Optimization: Continuing to execute on productivity initiatives to achieve $350 million in gross annualized savings by 2026.
CFO Transition: Transitioning to new CFO Amit Banati on May 12, 2025, to support the next chapter of Kenvue.
Strategic Pricing Investments: Implementing strategic price investments in the US to enhance brand competitiveness.
Macroeconomic Risks: Kenvue is not immune to significant macro shifts and seasonal variability, which could impact their performance.
Tariff Impact: The company estimates a gross impact of nearly $150 million for 2025 due to tariffs implemented by the US and retaliatory measures from other countries.
Supply Chain Challenges: Kenvue is facing higher costs for imported products and components due to tariffs, despite efforts to mitigate these through productivity initiatives and alternate sourcing.
Competitive Pressures: The company is experiencing competitive pressures in certain geographies, particularly affecting their Essential Health segment.
Destocking Issues: Destocking in China and other regions is negatively impacting sales, particularly in the Skin Health and Beauty segment.
Economic Factors: Retailers tightening order management in the US may shift volumes and require Kenvue to remain agile in response to changing market conditions.
Currency Fluctuations: The depreciation of the dollar is expected to have a 1% drag on top-line growth, which is an improvement from previous estimates.
Strategic Priorities: Kenvue is advancing three strategic priorities: 1) Activation of a new operating model to enhance innovation and marketing; 2) Optimization of cost structure through operational efficiencies; 3) Strengthening performance culture with new ways of working and collaboration.
Operational Milestone: Completion of the Transition Services Agreement program, finalizing the exit of over 2,300 TSAs without disruption.
New Headquarters: Moved into a new global headquarters in Summit, New Jersey, consolidating seven US locations to enhance collaboration.
Five Extraordinary Powers: Leveraging superior science, insights-led innovation, healthcare professional presence, breakthrough marketing, and seamless commerce to enhance brand potential.
Organic Sales Growth Outlook: Maintaining organic sales growth outlook for 2025 in the range of 2% to 4%.
Adjusted Operating Margin: Expecting adjusted operating margin to contract slightly for the full year due to increased costs from tariffs.
Adjusted Diluted EPS: Expecting adjusted diluted EPS for 2025 to be about flat versus last year, with low-single-digit headwind from currency.
Tariff Impact: Estimating nearly $150 million gross impact from tariffs for 2025, with ongoing mitigation actions being implemented.
Revenue Growth Management: Anticipating growth acceleration in the back half of the year driven by strong commercial activation and innovation.
Share Repurchase Program: Kenvue has not announced any share buyback program during this earnings call.
Dividend Program: There was no mention of a dividend program in the earnings call.
The earnings call reveals several concerning factors: a downward revision of the 2025 outlook, declining sales across segments, supply chain issues, and high SG&A costs. Despite strategic priorities and some brand successes, management's vague responses in the Q&A and lack of concrete guidance further dampen sentiment. The negative financial trends, combined with external pressures like tariffs and competitive challenges, suggest a negative stock price reaction in the short term.
The earnings call presents mixed signals. While EPS exceeded expectations and there is optimism for the second half of the year, current financial metrics such as declining organic sales and margins pose concerns. The lack of a shareholder return plan and supply chain challenges also weigh negatively. However, the company's innovation and strategic initiatives, along with positive consumer responses, provide a balanced outlook. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.
The earnings call reflects a challenging financial situation with declining organic sales, adjusted gross margin, and operating margin. The absence of a share buyback or dividend program further dampens investor sentiment. While management expressed optimism about innovation and growth in the latter half of the year, the lack of specific guidance and clarity in responses, particularly concerning tariff impacts and innovation success tracking, adds uncertainty. The overall sentiment is negative due to these factors, despite some positive consumer response and planned strategic investments.
The earnings call highlights several challenges: weak organic sales growth, distribution issues in Asia Pacific, and economic uncertainties. The lack of a share repurchase program and the operational separation risks add to investor concerns. Despite some positive elements like increased gross margin and brand investment, the overall sentiment is negative due to the financial outlook and management's vague responses during the Q&A. The absence of any strong positive catalysts, such as a new partnership or robust guidance, further supports a negative sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
